DreaMed Diabetes AI announced today that it received FDA clearance that expands its platform’s target population to cover type 1 and type 2 diabetes.
Tel Aviv, Israel-based DreaMed’s Advisor Pro AI clinical decision support system assists healthcare providers in the management of diabetes patients who use insulin pumps or injections and monitor their glucose using a continuous glucose monitor (CGM) and/or blood glucose meters.
DreaMed’s platform leverages the power of artificial intelligence (AI) to optimize insulin administration. The latest expanded clearance represents the fourth from the FDA for the platform, according to a news release.
The platform also received CE mark and had FDA clearance for people with type 1 diabetes. It is already deployed across leading diabetes treatment centers, including Yale New Haven Health, Texas Children’s Hospital, Unviersity of Florida and more.
”There are simply not enough endocrinologists to provide the expert level care that all people with diabetes require continuously,” DreaMed founder & CEO Eran Atlas said in the release. “DreaMed empowers the medical staff to treat significantly more patients by providing access to expert endocrinological advice in primary care settings. We can potentially help avoid thousands of unnecessary hospitalizations and medical complications for the community of people with diabetes and change the overall standards of care in this sector.
“The FDA clearance puts us on a path to help millions of people with diabetes and our next step is to develop and extend our solution to cover all injectable or oral medications for diabetes.”
